Pfizer's first-quarter results top estimates, while drugmaker boosts full-year profit outlook
By Eleanor Laise
Cancer and heart-disease treatments help cushion COVID product sales drop
Pfizer Inc. on Wednesday reported first-quarter profit and sales that beat analyst expectations and raised its full-year earnings guidance as cancer and heart-disease drugs helped offset plummeting COVID-19-related product sales.
The drugmaker reported net income of $3.115 billion, or 55 cents per share, down from $5.543 billion, or 97 cents per share, in the year-earlier period. Adjusted earnings per share of 82 cents, versus $1.23 a year earlier, beat the FactSet consensus of 51 cents. Revenues totaled $14.879 billion in the quarter, down 20% from a year earlier but ahead of the FactSet consensus of $13.874 billion.
An expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine Comirnaty, drove the year-over-year revenue decline. Paxlovid sales fell 50%, to $2.035 billion globally, while Comirnaty revenues dropped 88%, to $354 million.
Pfizer is looking for a fresh start after a rocky 2023, when the stock dropped more than 40% as some of the company's guidance proved overly optimistic.
Now, the company is looking for new growth in cancer treatments and advancing its pipeline. The first-quarter results come days after Pfizer scored its first U.S. regulatory approval for a gene therapy. The Food and Drug Administration gave a green light to Beqvez, a one-time treatment for hemophilia B that will have a list price of $3.5 million. Earlier this week, Pfizer and Genmab (GMAB) announced the FDA's full approval of Tivdak for treating recurrent or metastatic cervical cancer.
Pfizer's total first-quarter oncology revenues grew 18% from a year earlier, to $3.549 billion.
Sales of the Vyndaqel group of heart-disease drugs grew 66%, $1.137 billion, amid strong demand in the U.S. and Europe, Pfizer said.
Abrysvo, the respiratory syncytial virus vaccine that got FDA approval last year, generated $145 million in sales in the first quarter.
Pfizer is facing potential new competition in the pneumococcal vaccine market from Merck & Co. Inc. (MRK), whose investigational 21-valent pneumococcal vaccine could get U.S. regulatory approval by mid-June. Pfizer's Prevnar family of pneumococcal vaccines generated $1.691 billion in sales in the first quarter, up 7% from a year earlier.
Earnings in the quarter include an 11 cents per share favorable impact reflecting the actual number of Paxlovid treatment courses that carried emergency-use authorization labels and were ultimately returned by the U.S. government, Pfizer said.
Pfizer said it is still on track to save at least $4 billion by the end of this year as it previously projected under a broad cost-cutting program.
The company reaffirmed its full-year 2024 sales guidance of $58.5 billion to $61.5 billion and boosted its adjusted earnings per share outlook to a range of $2.15 to $2.35, up from $2.05 to $2.25.
Pfizer shares (PFE) gained 1.3% premarket on Wednesday and are down 11% in the year to date, while the S&P 500 is up 5.6%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-01-24 0826ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing